Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.

Advertisement

Related Content

FLAME Shoots LABA/LAMA Combos Up To First Choice In COPD
Boehringer Enters Asthma Market With New Indication For Spiriva Respimat
Novartis Respiratory Franchise Sits On FDA Launch Pad; Can It Achieve Orbit?
GSK, Novartis And Teva COPD Drugs Breeze Through EMA Together
FDA/IoM “Uncertainty” Conference Adds Uncertainty to Biogen Growth Plans For Tysabri
GSK At J.P.M. Updates On Breo Launch, Rare Diseases
GSK’s Big Push To Maintain Its Respiratory Reign
Theravance Preps For Separation As Breo Hits The U.S. Market
Novartis Once-Daily COPD Combo Safe, Effective And Ready For Filing – Everywhere But In The U.S.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel